Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Up 24.4% in December

Palisade Bio, Inc. (NASDAQ:PALI) was the target of a large increase in short interest during the month of December. As of December 31st, there was short interest totaling 15,949,282 shares, an increase of 24.4% from the December 15th total of 12,819,308 shares. Approximately 10.7% of the company’s shares are short sold. Based on an average trading volume of 5,642,145 shares, the short-interest ratio is currently 2.8 days. Based on an average trading volume of 5,642,145 shares, the short-interest ratio is currently 2.8 days. Approximately 10.7% of the company’s shares are short sold.

Palisade Bio Trading Down 5.1%

PALI traded down $0.09 during midday trading on Monday, reaching $1.66. The company’s stock had a trading volume of 9,796,958 shares, compared to its average volume of 5,545,150. Palisade Bio has a 1 year low of $0.53 and a 1 year high of $2.64. The stock’s 50-day moving average is $2.02 and its 200-day moving average is $1.42. The firm has a market capitalization of $247.34 million, a price-to-earnings ratio of -0.78 and a beta of 1.43.

Palisade Bio (NASDAQ:PALI) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.06). As a group, equities research analysts forecast that Palisade Bio will post -12.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on PALI shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Palisade Bio in a research note on Wednesday, October 8th. Citigroup reiterated a “buy” rating on shares of Palisade Bio in a report on Tuesday, November 11th. Clear Str raised Palisade Bio to a “strong-buy” rating in a research note on Monday, December 29th. B. Riley started coverage on Palisade Bio in a report on Friday, January 9th. They set a “buy” rating and a $7.00 target price for the company. Finally, Piper Sandler started coverage on Palisade Bio in a research note on Monday, December 29th. They issued an “overweight” rating and a $25.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Palisade Bio currently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.